Introduction called 'latency associated peptide' (LAP) and a 3∞ mature protein domain. The latent TGF-b may exist It is almost two decades since transforming growth as complexes with latent TGF-b binding proteins factor-b ( TGF-b) emerged from the backwater of (LTBP) of varying size [12] . After secretion, the latent modern biology [1, 2] . During the latter years, numer-molecules are proteolytically cleaved to the mature ous studies have been pursued to elucidate the biolo-forms. The in vivo process of this activation has not gical properties of this molecule. It is now well been fully elucidated, but evidence suggests the contrirecognized that TGF-b is a pleiotropic and complex bution of plasmin, a serine protease, to the cleavage cytokine involved in a wide range of cell behaviour of latent TGF-b [13] . [3 ] . Expression of TGF-b is observed in various embry-TGF-b is produced by various cell types, and the onic tissues and adult organs [4-6 ], and physiological major sources are platelets, bone, kidney, lung, and levels of TGF-b are supposed to be essential for normal placenta [3 ] . Expression of TGF-b receptors is ubiquitdevelopment, tissue repair, and maintenance of organ ous as well, and almost all cells respond to TGF-b in functions. On the other hand, overexpression of TGF-a cell-type-specific manner. Biological actions of TGFb is closely linked to certain pathologies including b are mediated by TGF-b receptors type I (RI ) and fibrogenesis [7 ] . In the kidney, a number of reports II ( RII ) [14 ] . TGF-b initially binds to RII that has a have suggested contribution of TGF-b to renal diseases constitutively active kinase. RI then binds to the TGF- [8 ] . In the process of glomerulonephritis, for example, b and is phosphorylated by RII. RI and RII form a upregulated TGF-b stimulates production of extracel-heteromeric complex and generate signals via serine lular matrix ( ECM), leading to excessive matrix depos-threonine kinases [14] . Although currently the signal transduction molecules responsible for propagating ition [9 ] . Several reviews have described the 'dark side' TGF-b's effects are not fully elucidated, recent investiof TGF-b in the kidney [7, 8, 10, 11] . In contrast, little gations have indicated the involvement of tumour attention has been paid to the 'bright side' of this suppressor proteins, mitogen-activated protein kinase molecule in the glomerulus. The aim of this article is pathways, and Mad family of molecules [14] [15] [16] . to address the therapeutically relevant potential of TGF-b possesses a diverse range of biological actions TGF-b in the process of glomerular inflammation. on mammalian cells, i.e. control of cell proliferation, adhesion, migration and phenotypic change, and thereby either positively or negatively regulates organo-physiological meaning of this observation is currently TGF-b in the generation of glomerulosclerosis (Figure 1 ). unknown. Based on the fact that TGF-b generally
In both acute and chronic glomerular diseases, uprefunctions as a differentiation factor [3 ] , the basal levels gulation of local TGF-b and accumulation of ECM of TGF-b could contribute to the maintenance of are concomitantly observed [7, 8, 10, 11] . In addition to normal glomerular structure and function.
abundant descriptive data based on immunohistologIn various pathological conditions, TGF-b is upreguical analyses, the crucial role of TGF-b1 in the accumulated in the glomerulus. The induction of TGF-b has lation of ECM in vivo has been demonstrated by been reported in experimental models including antiseveral investigators. Isaka et al. reported that introThy 1 glomerulonephritis, antiglomerular basement duction of a TGF-b1 cDNA into the glomerulus membrane (GBM) nephritis, Habu-venom glomeruloinduced ECM deposition [35 ] . Using an anti-TGF-b nephritis, puromycin-induced nephrosis, diabetic gloantiserum or a natural inhibitor of TGF-b, decorin, merulopathy, and nephropathy associated with ureteral
Border and co-workers demonstrated that systemic obstruction, as well as in human diseases such as IgA inhibition of TGF-b activity attenuated accumulation nephropathy, focal/segmental glomerulosclerosis, cresof ECM in an acute model of anti-Thy 1 glomerulocentic glomerulonephritis, lupus nephritis, diabetic nephritis [36] [37] [38] [39] . Similarly, Akagi et al. showed that nephropathy, and human immunodeficiency virus inhibition of local TGF-b1 expression via introduction nephropathy [7, 21] . In these pathological circum-of antisense oligodeoxynucleotides repressed the glomstances, TGF-b1, -b2 and -b3 may be similarly up-erular ECM deposition in the same experimental disregulated [21 ] .
ease [40 ] . These data provided evidence that The cell type responsible for TGF-b production in overexpression of TGF-b1 contributes to the accumuthe glomerulus is not fully elucidated, but mesangial lation of ECM in certain acute glomerulonephritides. cells may be one of major sources [9, 22] . In vitro,
In contrast to the accumulative data on the patholomesangial cells have the ability to secrete a substantial gical role of TGF-b1 in acute, reversible injury, amount of latent TGF-b1 and to convert it to the information is limited regarding whether long-term mature form [23, 24] . Glomeruli as well as cultured expression of TGF-b1 induces irreversible glomerulomesangial cells synthesize plasminogen activator sclerosis. One report has provided evidence on this [25, 26 ] that participates in the in vivo activation of issue. Sanderson et al. generated transgenic mice that TGF-b [13 ] . These findings suggest that mesangial express TGF-b1 under the control of an albumin cells are involved in both production and activation of promoter [41] . These mice abundantly produced biolo-TGF-b1 in the affected glomeruli. Platelets and infilt-gically active TGF-b1 in the liver, exhibited high levels rating cells, especially macrophages, are other potential of circulating TGF-b1 and developed progressive glomsources of TGF-b [27] [28] [29] . Currently it remains unclear erulosclerosis. This finding suggests the potential role whether or not resident endothelial or epithelial cells of overexpressed TGF-b in the generation of irreverscontribute to the production of glomerular TGF-b in ible glomerulosclerosis. pathological conditions.
Protective action of TGF-b against tissue injury
There is a body of literature that has described the Profibrotic action of TGF-b and its potential role 
in glomerulosclerosis
Excessive deposition of ECM is the characteristic feature of tissue fibrosis. Numerous reports have suggested the role of TGF-b in fibrogenesis of various organs including kidney, liver, lung, brain, joint, and skin [7] .
In glomerular disease, TGF-b has been regarded as a 'blackguard' that contributes to glomerulosclerosis [7, 8, 10, 11 ] . Generally, TGF-b induces deposition of ECM via stimulating production of matrix proteins, decreasing synthesis of ECM-degrading proteinases and upregulating synthesis of proteinase inhibitors [30] . In vitro, glomerular mesangial and epithelial cells produce collagens, fibronectin and proteoglycans in response to TGF-b1 [31 ] . TGF-b upregulates production of plasminogen activator inhibitor in isolated glomeruli and thereby downregulates the activity of plasminogen activator that contributes to activation of matrix-degrading metalloproteinases [32] . TGF-b also induces glomerular expression of integrins that extracellular matrix ( ECM ) via stimulating production of matrix enhances cell-matrix interaction [33] and stimulates proteins, decreasing the activity of ECM-degrading proteinases and facilitating ECM assembly.
ECM assembly [34 ] . These data suggest the role of it is well known that TGF-b enhances wound healing process and bone formation [42, 43] . This molecule acts as an autocrine tumour suppressor [44, 45] and may function as a repressor of atherosclerosis [46, 47] . TGF-b1 protects tissue cells from reperfusion injury via inhibiting adhesion of leukocytes to the endothelium [48] and/or opposing actions of certain cytokines and superoxide radicals [49] . This molecule is also useful for the treatment of septic shock by inhibiting production of nitric oxide [50] .
TGF-b is known to be a potent regulator of immune systems and inflammatory processes, generally functioning as an endogenous immunosuppressor. This molecule represses B cell proliferation and immunoglobulin secretion [51, 52] , mitogenesis and cytokine production by thymocytes/T lymphocytes [53, 54] and the function of natural killer cells [55] . TGF-b inhibits factors, and interferons a and c [58] .
In several inflammatory diseases, especially in autoimmune disorders, TGF-b exerts anti-inflammatory endothelial cells [67] [68] [69] . Similarly, the proliferative actions. Systemic administration of TGF-b attenuates response of isolated normal glomeruli is also inhibited the activity of experimental autoimmune diseases by TGF-b1 [70] . A possible mechanism of the antiproincluding arthritis, encephalomyelitis, insulitis, Sjö gren liferative action of TGF-b on glomerular cells is via syndrome and systemic lupus erythematosus without modulation of the cell-cycle machinery [15, 71, 72] . obvious unfavourable effects [59] [60] [61] [62] [63] . TGF-b also proIn glomerulonephritis, mitogenic mediators elaborlongs survival of cardiac allografts in mice [64] .
ated by infiltrating cells play crucial roles. In vitro, Constitutively expressed endogenous TGF-b1 is macrophage-derived IL-1 stimulates mesangial cells to essential for maintenance of normal immune and organ mitogenesis [73] . Our group recently reported that functions since targeted disruption of TGF-b1 via TGF-b1 is a predominant suppressor of macrophage homologous recombination induced multiorgan cytokine synthesis produced by mesangial cells [23 ] . inflammatory diseases and early death in mice [65, 66] . TGF-b may repress proliferation of glomerular cells, Organs isolated from the TGF-b1 null-mutant mice in part, via inhibiting release of cytokines by activated exhibited substantial expression of proinflammatory local macrophages. cytokines including interferon-c, tumour necrosis
In in vivo situations, however, the effect of TGF-b factor-a (TNF-a) and macrophage inflammatory pro-on glomerular cell proliferation is still controversial. tein-1a [65] , suggesting the critical role of TGF-b1 as Isaka et al. have reported that introduction of a TGFan endogenous, housekeeping immunosuppressant.
b1 gene into the normal rat glomerulus induced modest mitogenesis of resident cells [35] . Using antisense oligonucleotides, the same group recently showed that TGF-b as a potential 'defender' against glomerular suppression of TGF-b1 mRNA in anti-Thy 1 glominjury erulonephritis did not affect the hypercellularity [40] .
Using the similar experimental model and an ex vivo gene transfer approach, we have demonstrated that Typical pathological features of glomerulonephritis are mitogenesis of glomerular cells could be repressed by proliferation of resident cells and infiltration of leukointroduction of a mutated gene coding for the active cytes, especially macrophages. Based on the growthform of TGF-b1 [70 ] . Further studies will be needed inhibitory and immunosuppressive actions of TGF-b, to determine the in vivo effect of TGF-b on the it is not surprising that TGF-b has anti-inflammatory glomerular cell proliferation. effects during the process of glomerular injury. The 'bright side' of TGF-b in glomerulonephritis is addressed below ( Figure 2 ).
TGF-b and glomerular cell apoptosis
Apoptosis is an innate programme of cell suicide that TGF-b and glomerular cell proliferation is required for removal of unnecessary or damaged cells from bodily structures. In the glomerulus, apopIn general, TGF-b is an inhibitor of mitogenesis in glomerular cells. Several investigators have reported totic cell death is observed in several types of glomerular disease [74] [75] [76] and may play a role in the recovery that, in vitro, externally added TGF-b inhibits mitogenic responses of cultured mesangial, epithelial and from proliferative nephritis [77, 78] . Currently, how-ever, information is limited regarding the regulation of Generally, TGF-b upregulates production of ECM and proteinase inhibitors and downregulates synthesis apoptosis in the glomerulus. It has been reported that certain growth factors such as insulin-like growth of proteinases [30 ] . However, there are some exceptions in this story. Expression of matrix-degrading factor-I and II and basic fibroblast growth factor function as survival factors of cultured mesangial cells metalloproteinase-2 (MMP-2; gelatinase A; 72 kDa type IV collagenase) in cultured mesangial cells is [79 ] . In contrast, proinflammatory cytokines IL-1a, IL-1b and TNF-a may act as apoptosis inducers during enhanced by externally added TGF-b1 or transfection with a TGF-b1 cDNA [70, 96] . A similar effect was an early phase of glomerulonephritis [80, 81] .
TGF-b is known as a trigger of apoptosis in several observed in isolated glomeruli treated with TGF-b1 protein or transferred with a TGF-b1 gene [70] . This cell types including epithelial cells, hepatocytes, fibroblasts, endothelial cells, osteoclasts and leukocytes upregulation is due to transcriptional activation since TGF-b transfectants expressed higher levels of MMP-2 [82] [83] [84] [85] [86] . We recently found that TGF-b1 induces apoptosis in isolated glomeruli ( Y. Ishikawa and mRNA compared to mock transfectants [70 ] .
Consistent with these in vitro and ex vivo data, MMP-2 M. Kitamura, unpublished data). Cultured mesangial cells produce the active form of TGF-b1 [23, 24] , and is induced in nephritic glomeruli where TGF-b1 is upregulated [97 ] . Although the pathophysiological relmesangial cells expressing a dominant negative mutant of TGF-b RII are resistant to oxidant-initiated apop-evance of this observation remains to be determined, the negative contribution of TGF-b to degradation of totic death (M. Kitamura, unpublished data). These data suggest that TGF-b1 is an autocrine stimulator glomerular ECM may not be as simple as has been proposed. of mesangial cell apoptosis. In the acute, reversible model of anti-Thy 1 glomerulonephritis, Baker et al. reported that apoptosis of mesangial cells is the major TGF-b and cytokine responses of the glomerulus mechanism for resolution of glomerular hypercellularity [77] . In this experimental model, expression of Prototypic proinflammatory cytokines IL-1 and TNFa play a central role in various inflammatory processes TGF-b1 is sustained over the recovery phase [9 ] . This molecule might contribute to the resolution of inflamed [98] . In the kidney, IL-1 and TNF-a are involved in several glomerular diseases [99, 100] . These cytokines glomeruli from hypercellular states via inducing apoptosis.
stimulate mesangial cells to mitogenesis and production of inflammatory mediators including cytokines, chemokines, neutral proteinases, bioactive lipids and reactive TGF-b and homeostasis of ECM oxygen/nitrogen species [99, 101, 102] . These mediators subsequently induce cell proliferation, leukocyte influx ECM is known to have profound effects on the regulation of cell behaviour [87 ] . In the glomerulus, mesang-and destruction of glomerular structure, leading to progression of injury. TGF-b has several actions that ial cells are surrounded by mesangial matrix consisting of basement-membrane-type collagens, glycoproteins counteract against these effects [98, [103] [104] [105] . We and others previously reported that mesangial cells and/or and proteoglycans [88] . Using artificial gel matrices reconstituted in vitro, we and others previously glomeruli treated with TGF-b1 exhibited depressed responses to IL-1b and TNF-a [70, [106] [107] [108] . In some reported that three-dimensional ECM inhibited migration, proliferation and expression of a-smooth muscle particular pathological situations, TGF-b could function as a 'defender' of the glomerulus by opposing the actin in cultured mesangial cells [89] [90] [91] [92] . A gene transfection study explored that mesangial cells with actions of these proinflammatory cytokines.
Preliminary evidence showed that administration of aberrant matrix-degrading activity exhibited accelerated mitogenesis and migration in ECM [93 ] . This line decorin, a natural inhibitor of TGF-b, into rats subjected to anti-GBM nephritis induced deterioration of of evidence implies that the mesangial matrix controls the behaviour of mesangial cells and maintains their the disease; i.e. enhanced glomerular cellularity, accelerated crescent formation, and increased proteinuria differentiated phenotype in the glomerulus. This hypothesis has been further supported by our recent findings [109] . In this experimental model, IL-1 plays a crucial role in the generation of glomerular injury [110, 111] . [92, 94] . Prolonged culture of mesangial cells forms nodular structures composed of cells and surrounding If TGF-b has an opposing effect on IL-1 action, the anti-inflammatory potential of TGF-b in this nephritis extracellular matrix, that mimics the situation in the glomerular mesangium. Incorporation of mesangial model is raised. cells into this 'natural' matrix structure allows for transition of the cellular phenotype toward deactiva-TGF-b and macrophage function tion and differentiation [94] . Interestingly, the differentiated phenotype of mesangial cells in nodules was One of the most common pathological features of glomerular disease is infiltration of mononuclear cells. correlated with upregulation of TGF-b1 mRNA [94] . Basal levels of glomerular TGF-b1, an important regu-These cells are mainly monocytes/macrophages, with T lymphocytes present in smaller numbers [112 ] . lator of ECM homeostasis [95 ] , may participate in the maintenance of ECM structures and thereby could Several investigators have disclosed a link between macrophage infiltration and histological damage in the contribute to the maintenance of differentiated phenotypes of glomerular cells.
glomerulus, e.g. mesangial/endothelial proliferation, matrix accumulation, and crescent formation [113] . cytokine synthesis would be a potential strategy for therapeutic intervention in glomerular disease. These data suggest that glomerular macrophages play Previous reports have provided evidence that TGFa crucial part in the generation of glomerular injury.
b inhibits production of IL-1a, TNF-a, lymphotoxin, The pathological importance of macrophages has been and interferon-c by peripheral blood mononuclear cells investigated more extensively in several experimental and peritoneal macrophages [127, 128] . We recently glomerulonephritis [113 ] . Using these models in comfound that cultured mesangial cells secrete a factor bination with manipulations for macrophage depletion, that strongly inhibits production of IL-1b, IL-6, TNFa close correlation between macrophage accumulation a and monocyte chemoattractant protein-1 by activated and onset of glomerular injury has been established. macrophages [23, 129] . Using a specific neutralizing TGF-b is a prominent 'macrophage deactivator' antibody, we have identified that this active entity is [114 ] . This molecule suppresses functions of macro-TGF-b1. phages at picomolar concentrations [57 ] . From this To further investigate the suppressive action of mesviewpoint, TGF-b may act as a potential 'defender' angial cell-derived TGF-b1 on macrophages in vivo, against macrophage-mediated glomerular injury.
reporter macrophages prestimulated with LPS were Adhesion. Adhesiveness is an important factor that transferred into normal rat glomeruli or glomeruli in determines retention of macrophages at inflammatory the regeneration phase of acute glomerulonephritis sites. Adhesion also serves as a priming stimulus for where mesangial TGF-b1 is upregulated [130, 131] . In functional alteration in monocytes/macrophages; e.g. the normal glomeruli, cytokine-inducible metalloadhesion promotes differentiation of monocytes to proteinases were markedly induced in resident glomertissue macrophages and induces migration, phagocytular cells following the transfer of activated osis, respiratory oxidative burst, and expression of macrophages. In contrast, this induction was repressed certain cytokines and proto-oncogenes [115] [116] [117] [118] [119] .
in the TGF-b1-expressing, nephritic glomeruli. This These findings indicate that adhesiveness of macroresult points to the novel potential of glomerular TGFphages within the glomerulus controls macrophage b1 to suppress macrophage-mediated activation of function. glomerular cells. Macrophages use scavenger receptors and comple-Generation of reactive oxygen metabolites. A body of ment receptor 3 (CR3; b2 integrin) to adhere to local evidence has suggested pathological roles of reactive tissues [120, 121] . It has been reported that TGF-b1 oxygen species in a wide range of glomerular injury downregulates expression of these adhesion receptors [132] . The oxygen radical metabolites generated by in macrophages [122, 123] . Consistent with these data, infiltrating cells and/or resident glomerular cells induce we recently reported that mesangial cell-derived TGF-degradation of GBM and inhibit de novo synthesis of b1 impairs adhesiveness of macrophages in vitro [24] . heparan sulphate proteoglycans, leading to proteinuria Furthermore, compared to adherent cells, detached [133] . Oxidants also initiate glomerular expression of macrophages showed blunted expression of cytokines chemoattactants of monocytes, reduce the activity of in response to lipopolysaccharide (LPS ).
ADPase that inhibits thrombus formation, and thereby In the acute, reversible model of anti-Thy 1 glom-contribute to the generation of proliferative glomeruloerulonephritis in rats, a transient accumulation of nephritis [133] . monocytes/macrophages is observed within 24 h [124 ] .
In glomerular inflammation, major sources of reactThe increased number of local macrophages is sus-ive oxygen species are neutrophils and monocytes/ tained for up to 7 days and declines thereafter. At macrophages [133 ] . These cells exhibit a respiratory day 14, the majority of the inflammatory macrophages burst with marked increase in the generation of reactive disappear from the glomerulus [124] , probably by oxygen metabolites in response to various stimuli. trafficking to draining lymph nodes [125] . In this Prevention of the oxidant production by infiltrating nephritis model, upregulation of glomerular TGF-b1 cells would be a potential therapeutic approach to is detected from day 4 and continues at least until glomerulonephritis. day 14 [9 ] . Interestingly, the anti-Thy 1 antibody Enhanced generation of reactive oxygen metabolites re-injected at day 14 does not lead to macrophage has been reported in macrophages isolated from glomaccumulation [124 ] . The upregulation of TGF-b1 in eruli subjected to anti-GBM nephritis and anti-Thy 1 this nephritis model is thus correlated not with accumu-glomerulonephritis [134, 135] . It is known that TGFlation but with reduced macrophage retention in the b1 and TGF-b2 strongly inhibit the respiratory burst glomerulus.
of macrophages at picomolar concentrations [57 ] . In Cytokine synthesis. Macrophage-derived proinflam-both experimental diseases, TGF-b is upregulated in matory cytokines play crucial roles in glomerular the glomerulus [7] . TGF-b possibly functions as a injury. For example, IL-1, IL-6 and TNF-a are detect-defender molecule in these pathological circumstances able in several types of glomerular disease where via deactivation of macrophages. macrophages are implicated [100 ]. These macrophage-Production of nitric oxide (NO). The -arginine-NO derived factors induce cell proliferation, overproduc-pathway is involved in the physiological function of tion of ECM, and secretion of inflammatory mediators many mammalian organs, including the kidney. In the by glomerular cells and contribute to glomerular injury glomerulus, constitutively expressed NO synthase (NOS ) is observed. The basal generation of NO parti- [73, 126 ] . In this context, inhibition of macrophage cipates in the regulation of glomerular haemodynamics model may be an outcome of immune-complexmediated glomerular injury. [136 ] . In contrast, during glomerulonephritis, the generation of NO increases to picomolar levels via the By combining an experimental model of glomerulonephritis with manipulations to reduce TGF-b activity inducible NO synthase (iNOS) principally expressed in infiltrating macrophages [137] . Increased glomerular in vivo, several studies have suggested the pathogenic contribution of TGF-b [36] [37] [38] [39] [40] . However, it should be production of nitrite has been reported in anti-GBM nephritis, Heymann nephritis, anti-Thy 1 nephritis, pointed out that all these studies utilized the acute model of anti-Thy 1 glomerulonephritis in the rat. This and in situ immune complex glomerulonephritis [137] .
The pathophysiological role of NO during glomer-experimental model mimics mesangial proliferative glomerulonephritis in human, but the pathological ular inflammation is controversial. Its potentially beneficial actions include inhibition of thrombosis, changes are transient and reversible. After several weeks, the lesions spontaneously disappear without scavenging of superoxide, repression of cytokine expression and inhibition of mesangial cell prolifera-irreversible sclerosis or scarring [152, 153] . This is obviously different from the human counterpart. To detertion [138] [139] [140] [141] . On the other hand, a high concentration of NO is cytotoxic, and macrophage-derived NO mine whether inactivation of TGF-b provides a general therapeutic strategy for progressive glomerulosclerosis, possibly contributes to glomerular injury [137 ] . Indeed, several reports demonstrated that administration with two-shot models of anti-Thy 1 nephritis [22, 124] or other chronic experimental diseases must be tested. NOS inhibitors attenuates macrophage-mediated glomerular injury including autoimmune glomeruloIn the acute, reversible model of anti-Thy 1 glomerulonephritis, expression of TGF-b1 is maintained nephritis and anti-Thy 1 nephritis [142, 143] .
Several endogenous mediators function as inhibitors during the reconstruction of the normal glomerulus [9] . Since, generally, TGF-b plays an important role of iNOS expression in macrophages. Those include IL-4, IL-10 and TGF-b family of molecules [144] . It in the repair of injured tissues [42] , this molecule could contribute to the repair of affected glomeruli in this is well known that TGF-b1, -b2 and -b3 inhibit generation of NO by activated macrophages [145 ] . TGF-b1 model. Indeed, in vivo inactivation of TGF-b1 attenuates ECM accumulation in the glomerulus, whereas it inhibits iNOS expression at multiple levels; i.e. it decreases stability of iNOS mRNA, reduces translation disturbs repair of mesangiolysis caused by anti-Thy 1 antibodies ( Dr Seiya Okuda, personal communicaof the mRNA, and increases degradation of iNOS protein [146 ] . In certain pathological conditions, loc-tion). The role of TGF-b1 in the repairing process of the glomerulus should be investigated further in a ally produced TGF-b may act against the NO-mediated glomerular injury. novel context. As noted above, TGF-b is a prominent macrophage deactivator that inhibits production of potentially injurious mediators including cytokines and reactive
Unanswered questions
oxygen/nitrogen species. Therapeutic utility of TGF-b should therefore be tested in certain types of glomerular injury, especially in macrophage-mediated glomerular Accumulative data have proposed a role for TGF-b in glomerular injury, especially in the generation of glom-diseases. Autoimmune-associated glomerular disease is another target of therapeutic intervention via TGF-b. erulosclerosis. However, this is largely dependent on histology-based studies to detect TGF-b expression in It has been reported that intramuscular injection of a TGF-b1 cDNA suppressed production of autoantibodaffected glomeruli. Since expression of certain molecule in disease sites does not directly mean its pathological ies in lupus-prone mice [63 ] . Using the same gene transfer technique, Raz et al. reported that long-term significance, more definitive evidence is required to determine the role of TGF-b. For this purpose, gene treatment of murine systemic lupus erythematosus with a TGF-b1 gene prolonged survival, improved renal transfer strategies would provide useful tools [147, 148] . However, current in vivo gene transfer methods only function, and suppressed glomerular inflammation [154] . allow for transient expression of transgenes [149, 150] , and long-term action of TGF-b has not been tested in
In this review, we did not emphasize the effect of TGF-b on functions of infiltrating cells other than vivo. It is necessary to clarify whether or not sustained, local expression of TGF-b1 is sufficient for the genera-macrophages. However, this molecule may affect local accumulation and activity of other leukocytes, includtion of irreversible glomerulosclerosis and scarring.
A transgenic approach has given one answer to this ing neutrophils, another important player in the acute phase of glomerular inflammation [155 ] . It has been question. Sanderson et al. generated transgenic mice that express TGF-b1 in the liver. These mice developed reported that TGF-b inhibits endothelial production of IL-8, a neutrophil chemoattractive/activating factor progressive glomerulosclerosis, leading to chronic renal failure [41 ] . However, this is not an appropriate model [156 ] . Furthermore TGF-b suppresses both adhesiveness of neutrophils to the endothelium and their to examine the local, direct action of TGF-b1 in the glomerulus because; (i) the levels of circulating mature transmigration into the extravascular space via inhibiting the endothelial expression of E-selectin and/or IL-8 TGF-b were extremely high, and (ii) massive deposition of immunoglobulins was observed in the glomer- [156, 157] . Since infiltration of neutrophils is an essential event for certain glomerular inflammation, TGF-b ulus [151] . The glomerulosclerosis observed in this 
